Aripiprazole (pronounced /ˌɛərɨˈpɪprəzoʊl/ AIR-i-PIP-rə-zohl; brand names: Abilify, Abilify Discmelt, Aripiprex) is an atypical antipsychotic and antidepressant used in the treatment of schizophrenia, bipolar disorder, and clinical depression. It was approved by the US Food and Drug Administration (FDA) for schizophrenia on November 15, 2002, for acute manic and mixed episodesmajor depressive disorder on November 20, 2007 and to treat irritability in children with autism on 20 November 2009.Otsuka in Japan, and in the United States, Otsuka America markets it jointly with Bristol-Myers Squibb. associated with bipolar disorder on October 1, 2004, as an adjunct for Aripiprazole was developed by
 

Aripiprazole has been approved by the FDA for the treatment of schizophrenia.

 Bipolar disorder

Aripiprazole has been approved by the FDA for the treatment of acute manic and mixed episodes, in both pediatric patients aged 10–17 and in adults.Several double-blind, placebo-controlled trials support this use. In addition, it is often used as maintenance therapy, either on its own or in conjunction with a mood stabilizer such as lithium or valproate. This use is also supported by a handful of studies. Aripiprazole is at least as effective as haloperidol at reducing manic symptoms,^{[unreliable source?]} and is much better tolerated by patients.
Aripiprazole's use as a monotherapy in bipolar depression is more controversial. While a few pilot studies have found some effectiveness (with one finding a reduction in anhedonia symptoms), two large, double-blind, placebo-controlled studies found no difference between aripiprazole and placebo.One study reported depression as a side effect of the drug.

In 2007, aripiprazole was approved by the FDA for the treatment of unipolar depression when used adjunctively with an antidepressant medication.It has not been FDA-approved for use as monotherapy in unipolar depression.